Pemetrexed

The standard dosage of Pemetrexed is calculated based on the patient's Body Surface Area (BSA), which is determined using height and weight.

• Non-Squamous Non-Small Cell Lung Cancer (Combination Therapy): The recommended dose is 500 mg/m² administered as an intravenous infusion over 10 minutes on Day 1 of each 21-day cycle. This is typically given in combination with cisplatin (75 mg/m²).
• Non-Squamous Non-Small Cell Lung Cancer (Single-Agent Maintenance or Second-line): The recommended dose is 500 mg/m² as an intravenous infusion over 10 minutes on Day 1 of each 21-day cycle.
• Malignant Pleural Mesothelioma: The recommended dose is 500 mg/m² administered as an intravenous infusion over 10 minutes on Day 1 of each 21-day cycle, in combination with cisplatin (75 mg/m²).

Mandatory Premedication Regimen:

To reduce toxicity, all patients must follow a specific supplementation schedule:

1. 1Folic Acid: 400 mcg to 1000 mcg orally once daily, starting at least 5 days before the first dose of Pemetrexed and continuing for 21 days after the last dose.
2. 2Vitamin B12: 1000 mcg administered as an intramuscular injection during the week preceding the first dose and every three cycles thereafter.
3. 3Dexamethasone: 4 mg orally twice daily for three days, starting the day before the Pemetrexed infusion, to prevent skin reactions (rashes).

Pemetrexed is not currently approved for use in pediatric patients. The safety and effectiveness of Pemetrexed in children and adolescents have not been established. Clinical trials in pediatric populations have not demonstrated significant anti-tumor activity for the types of cancers typically treated with this agent in adults.

Renal Impairment

Dosage adjustments are critical based on kidney function, measured by Creatinine Clearance (CrCl):

• CrCl ≥ 45 mL/min: No dosage adjustment is generally required.
• CrCl < 45 mL/min: Pemetrexed should not be administered. There is insufficient data to recommend a safe dose for patients with significant renal impairment, and the risk of life-threatening toxicity is high.

Hepatic Impairment

Pemetrexed has not been extensively studied in patients with severe hepatic (liver) impairment (bilirubin > 1.5 times the upper limit of normal). However, for patients with mild to moderate hepatic impairment, no specific dose adjustments are typically required, provided renal function remains adequate.

Elderly Patients

In clinical trials, no overall differences in safety or effectiveness were observed between patients 65 years of age and older and younger patients. However, because elderly patients are more likely to have decreased renal function, careful monitoring of Creatinine Clearance is essential.

Pemetrexed is administered in a clinical setting (hospital or infusion center) by trained healthcare professionals.

• Administration: It is given as a 10-minute IV infusion. It is not a continuous infusion.
• Food and Drink: There are no specific food restrictions on the day of the infusion. However, staying well-hydrated is important for kidney health.
• Storage: Unopened vials should be stored at room temperature (20°C to 25°C). Reconstituted and diluted solutions are stable for a limited time and must be used or refrigerated as per the manufacturer's instructions.

Because Pemetrexed is administered on a strict 21-day cycle by a medical team, a 'missed dose' usually refers to a delayed appointment. If you miss an infusion appointment, contact your oncology clinic immediately to reschedule. Delays may be necessary if your blood counts (white cells, platelets) are too low or if you have not taken your folic acid and B12 supplements correctly.

Signs of a Pemetrexed overdose include severe bone marrow suppression (leading to infection, bleeding, or extreme fatigue), severe skin rashes, and intense gastrointestinal distress (diarrhea, mucositis). In the event of an accidental overdose, treatment is supportive. Healthcare providers may administer leucovorin (folinic acid) as an 'antidote' to help rescue healthy cells from the effects of the drug.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not skip your vitamin supplements, as they are vital for your safety while taking Pemetrexed.

Most patients receiving Pemetrexed will experience some side effects, though the severity is often managed through vitamin supplementation and premedication.

• Myelosuppression (Bone Marrow Suppression): This is the most common and significant side effect. It includes anemia (low red blood cells), which causes fatigue and shortness of breath; neutropenia (low white blood cells), which increases the risk of infection; and thrombocytopenia (low platelets), which can cause easy bruising or bleeding. According to FDA data, grade 3-4 neutropenia occurs in approximately 15-20% of patients.
• Fatigue: A profound sense of tiredness or exhaustion that does not always improve with rest. This can be caused by the drug itself or the underlying cancer.
• Gastrointestinal Issues: Nausea and vomiting are common but usually manageable with modern anti-nausea medications. Loss of appetite (anorexia) and diarrhea also occur frequently.
• Pharyngitis and Stomatitis: Sore throat or painful mouth sores (mucositis). This can make eating or drinking difficult.
• Skin Rash: A red, itchy rash may develop. This is why dexamethasone is prescribed as a premedication.

• Neuropathy: Numbness, tingling, or a 'pins and needles' sensation, usually in the hands or feet.
• Increased Liver Enzymes: Temporary elevations in ALT or AST levels, indicating mild liver stress.
• Conjunctivitis: Redness, itching, or watering of the eyes (pink eye).
• Renal Dysfunction: A rise in serum creatinine levels, indicating that the kidneys are not filtering waste as efficiently.
• Dyspnea: Shortness of breath, which may be related to lung inflammation or anemia.

• Radiation Recall: A severe inflammatory skin reaction that occurs in an area previously treated with radiation therapy. The skin may look and feel like a severe sunburn.
• Interstitial Pneumonitis: Inflammation of the lung tissue that can cause scarring and permanent breathing difficulties.
• Hemolytic Anemia: A condition where red blood cells are destroyed faster than they can be made.
• Bullous Skin Reactions: Severe blistering conditions, such as Stevens-Johnson Syndrome (SJS) or Toxic Epidermal Necrolysis (TEN), which are medical emergencies.

> Warning: Stop taking Pemetrexed and call your doctor immediately if you experience any of these symptoms. These may indicate life-threatening complications.

1. 1Signs of Infection: Fever (100.4°F / 38°C or higher), chills, sore throat, or cough. Because Pemetrexed lowers your white blood cell count, an infection can become life-threatening very quickly (sepsis).
2. 2Unusual Bleeding or Bruising: This includes nosebleeds, bleeding gums, or black/tarry stools, which may indicate dangerously low platelet counts.
3. 3Severe Diarrhea: More than 4-6 episodes per day or diarrhea accompanied by abdominal pain and fever, which can lead to severe dehydration and electrolyte imbalances.
4. 4Chest Pain or Sudden Shortness of Breath: This could indicate a pulmonary embolism (blood clot in the lung) or heart complications.
5. 5Severe Skin Reactions: Rapidly spreading rash, blistering of the skin or mucous membranes (mouth, eyes, genitals), or skin peeling.
6. 6Signs of Kidney Failure: Significant decrease in urine output, swelling in the ankles or feet, or sudden weight gain.

While many side effects of Pemetrexed resolve after the treatment is completed, some may persist.

• Kidney Damage: Chronic use or repeated episodes of acute kidney injury can lead to long-term reduction in renal function.
• Peripheral Neuropathy: In some cases, the numbness or tingling in the extremities may take months to resolve or may become permanent.
• Lung Scarring: If pneumonitis occurs, it can leave behind fibrotic (scar) tissue in the lungs, affecting long-term breathing capacity.

There are currently no FDA black box warnings for Pemetrexed. However, the drug carries significant warnings regarding myelosuppression and renal failure that are emphasized in the 'Warnings and Precautions' section of the official prescribing information. The requirement for vitamin supplementation is considered a 'critical safety measure' to prevent the severe toxicities that were observed in early clinical development.

Report any unusual symptoms to your healthcare provider. Keeping a daily log of how you feel can help your oncology team adjust your care plan.

Pemetrexed is a high-alert medication that requires close supervision by an oncologist. The most critical safety aspect of Pemetrexed therapy is the mandatory use of folic acid and vitamin B12. Failure to take these supplements as directed significantly increases the risk of 'Grade 4' toxicities, which are life-threatening. Patients must also be aware that Pemetrexed is specifically for non-squamous lung cancer; it is ineffective and potentially harmful for those with squamous cell histology.

No FDA black box warnings for Pemetrexed. Despite the absence of a boxed warning, the risk of severe bone marrow suppression is the primary clinical concern and is managed through strict adherence to the supplementation protocol and blood count monitoring.

• Myelosuppression: Pemetrexed can severely suppress the bone marrow's ability to produce blood cells. This is usually 'dose-limiting,' meaning the dose may need to be lowered or delayed if counts do not recover. The 'nadir' (the point when blood counts are lowest) typically occurs 10-12 days after the infusion.
• Renal Toxicity: Pemetrexed is eliminated by the kidneys. It can cause acute kidney injury, especially in patients who are dehydrated or taking other drugs that affect the kidneys (like NSAIDs). Renal function must be checked before every single dose.
• Skin Reactions: Severe and even fatal skin reactions have been reported. Premedication with dexamethasone is essential to reduce the frequency and severity of these rashes.
• Radiation Recall: Patients who have had radiation therapy in the past may experience a 'recall' reaction where the skin in the treated area becomes inflamed. This can occur weeks or even years after the original radiation.
• Third-Space Fluid Accumulation: If you have fluid around your lungs (pleural effusion) or in your abdomen (ascites), Pemetrexed can leak into this fluid and then slowly leak back into your bloodstream. This acts like a 'slow-release' reservoir, keeping the drug in your system much longer than intended and greatly increasing toxicity. Your doctor may need to drain this fluid before giving you Pemetrexed.

Patients undergoing Pemetrexed treatment require frequent laboratory monitoring:

• Complete Blood Count (CBC): To monitor white blood cells, red blood cells, and platelets. This is typically done before each dose and sometimes at the 'nadir' (mid-cycle).
• Renal Function Tests: Serum creatinine and calculated Creatinine Clearance (CrCl) must be checked before every dose. If CrCl is below 45 mL/min, the drug cannot be given.
• Liver Function Tests (LFTs): Periodic monitoring of bilirubin and transaminases (ALT/AST) to ensure the liver is processing the drug and other medications safely.

Pemetrexed can cause significant fatigue and, in some cases, dizziness or 'chemo brain' (cognitive clouding). Patients should observe how the drug affects them before attempting to drive or operate heavy machinery. If you feel excessively tired or weak, avoid these activities.

There is no direct contraindication between alcohol and Pemetrexed; however, alcohol can contribute to dehydration and may irritate the lining of the mouth and throat, worsening mucositis. Alcohol can also put additional strain on the liver. It is generally advised to limit alcohol consumption during chemotherapy.

Pemetrexed does not cause a physical withdrawal syndrome and does not require tapering. However, stopping treatment early can allow the cancer to grow or spread. If you wish to discontinue treatment due to side effects, discuss this with your oncologist, who may suggest a dose reduction or an alternative therapy.

> Important: Discuss all your medical conditions, especially any history of kidney disease or fluid accumulation, with your healthcare provider before starting Pemetrexed.

While there are few absolute contraindications for drug combinations with Pemetrexed, the most significant risk involves Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) in patients with reduced kidney function.

• NSAIDs (e.g., Ibuprofen, Naproxen, Celecoxib) + Renal Impairment: In patients with a Creatinine Clearance (CrCl) between 45 and 79 mL/min, NSAIDs with short half-lives (like ibuprofen) should be avoided for 2 days before, the day of, and 2 days after Pemetrexed administration. NSAIDs with long half-lives (like naproxen or piroxicam) should be avoided for at least 5 days before, the day of, and 2 days after. Using them together can cause Pemetrexed levels to skyrocket, leading to fatal bone marrow and gastrointestinal toxicity.

• Nephrotoxic Agents: Drugs that are known to damage the kidneys can slow the elimination of Pemetrexed. This includes certain antibiotics (aminoglycosides like gentamicin), antifungal medications (Amphotericin B), and other chemotherapy agents (like Cisplatin or Carboplatin). While Cisplatin is often used with Pemetrexed, the combination requires very careful monitoring of kidney function.
• Probenecid: This medication, often used for gout, interferes with the renal secretion of many drugs. It can significantly increase the concentration of Pemetrexed in the blood, increasing the risk of severe side effects.

• Loop Diuretics (e.g., Furosemide): These can affect kidney function and hydration status. While not strictly forbidden, patients should be monitored for dehydration, which can increase Pemetrexed toxicity.
• Warfarin: Chemotherapy can sometimes alter the way the body processes blood thinners. Patients on Warfarin may need more frequent INR (clotting time) checks when starting or stopping Pemetrexed.

There are no known direct interactions between Pemetrexed and specific foods. However, the 'interaction' with vitamins is the most important:

• Folic Acid and B12 Deficiency: A lack of these vitamins in the diet or through supplements is a 'negative interaction' that makes Pemetrexed much more toxic.
• Hydration: Dehydration is a major risk factor for Pemetrexed-induced kidney damage. Patients should aim for adequate fluid intake unless otherwise restricted by their doctor.

• High-Dose Vitamin C: Some studies suggest that very high doses of antioxidants might interfere with the oxidative stress that chemotherapy uses to kill cancer cells.
• St. John's Wort: While Pemetrexed is not metabolized by the CYP3A4 system, St. John's Wort can interact with many other medications used alongside Pemetrexed (like anti-nausea drugs or pain medications).
• Folate-containing supplements: While a standard 400-1000 mcg folic acid supplement is required, patients should avoid 'megadosing' on folic acid (e.g., 5mg or more) unless specifically directed, as excessively high levels might theoretically reduce the drug's efficacy.

Pemetrexed does not typically interfere with the chemical assays used in lab tests, but its biological effects will be reflected in:

• Elevated Creatinine: A biological sign of kidney stress.
• Low Blood Counts: A biological sign of bone marrow suppression.
• Liver Enzyme Elevation: A biological sign of hepatic stress.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially any over-the-counter pain relievers like Advil, Aleve, or Motrin.

There are specific circumstances where Pemetrexed must never be used due to the extreme risk of harm:

1. 1Severe Hypersensitivity: Patients who have had a documented, severe allergic reaction (anaphylaxis) to Pemetrexed or any of the ingredients in the formulation (such as mannitol) must not receive the drug. Symptoms of such a reaction include swelling of the throat, difficulty breathing, and a rapid drop in blood pressure.
2. 2Severe Renal Impairment (CrCl < 45 mL/min): Because the kidneys are the only significant way the body removes Pemetrexed, giving the drug to someone with a Creatinine Clearance below 45 mL/min is extremely dangerous. The drug will accumulate to toxic levels, likely causing fatal bone marrow failure or severe gut damage.
3. 3Yellow Fever Vaccine: Like many chemotherapy agents that suppress the immune system, Pemetrexed should not be given concurrently with live vaccines like the Yellow Fever vaccine, as it can lead to a generalized, potentially fatal infection from the vaccine itself.

These are conditions where the doctor must carefully weigh the benefits of the drug against the potential risks:

• Active Infection: Because Pemetrexed lowers white blood cell counts, giving it to someone with an ongoing infection can prevent the body from fighting the infection effectively. The infection should generally be resolved before starting a new cycle.
• Third-Space Fluid (Pleural Effusion/Ascites): As mentioned, fluid collections can act as a reservoir for the drug. While not an absolute contraindication, the fluid should be drained (thoracentesis or paracentesis) prior to treatment to ensure safe drug clearance.
• Poor Performance Status: Patients who are very weak or bedbound (ECOG performance status 3 or 4) may not tolerate the toxicities of Pemetrexed well, and the risks of treatment may outweigh the benefits.

There is no significant evidence of cross-sensitivity between Pemetrexed and other non-folate chemotherapy agents. However, patients who have had severe reactions to other folate-based drugs (like Methotrexate) should be monitored very closely, as the chemical structures are related, though their specific enzyme targets differ.

> Important: Your healthcare provider will evaluate your complete medical history, including your kidney function and any previous reactions to chemotherapy, before prescribing Pemetrexed.

Pemetrexed is considered highly teratogenic (can cause birth defects or fetal death). According to the FDA, Pemetrexed is classified as a drug that can cause fetal harm when administered to a pregnant woman.

• Risks: Animal studies have shown that Pemetrexed causes malformations of the skeleton and internal organs.
• Contraception (Females): Females of reproductive potential should use effective contraception during treatment and for at least 6 months after the final dose.
• Contraception (Males): Because Pemetrexed can be present in seminal fluid and may damage sperm DNA, men with female partners of reproductive potential should use effective contraception during treatment and for 3 months after the last dose.

It is not known if Pemetrexed is excreted in human breast milk. However, because many drugs are excreted in milk and because of the potential for serious adverse reactions in nursing infants, women are advised not to breastfeed during treatment with Pemetrexed and for one week after the final dose.

Pemetrexed is not approved for use in children. Clinical trials in pediatric patients with solid tumors (such as osteosarcoma or Ewing sarcoma) did not show enough activity to justify its use. Furthermore, the long-term effects of Pemetrexed on growth and development in children are unknown.

While clinical trials did not show a major difference in how Pemetrexed works in patients over 65 compared to younger patients, the risk of side effects is higher in the elderly. This is primarily because kidney function naturally declines with age. Older adults are more likely to experience severe neutropenia and infections. Close monitoring of renal function and blood counts is paramount in this population.

Renal impairment is the most significant factor in Pemetrexed toxicity.

• Mild to Moderate: Patients with a CrCl between 45 and 79 mL/min can receive the standard dose but must be extremely cautious with the use of NSAIDs.
• Severe: Patients with a CrCl < 45 mL/min should not receive Pemetrexed.
• Dialysis: Pemetrexed is not recommended for patients on hemodialysis or peritoneal dialysis, as there is no established safe dosing regimen for these patients.

Pemetrexed is not primarily metabolized by the liver. Patients with mild hepatic impairment (bilirubin ≤ 1.5 x ULN and/or AST/ALT ≤ 3 x ULN) do not typically require dose adjustments. However, Pemetrexed has not been studied in patients with severe liver disease (Child-Pugh Class C), and such patients should be treated with extreme caution.

> Important: Special populations require individualized medical assessment. Always inform your oncology team if you are pregnant, planning to become pregnant, or have any history of kidney or liver disease.

Pemetrexed is a multi-targeted antifolate. Its primary mechanism is the inhibition of three enzymes essential for the de novo synthesis of thymidine and purine nucleotides: Thymidylate Synthase (TS), Dihydrofolate Reductase (DHFR), and Glycinamide Ribonucleotide Formyltransferase (GARFT).

Upon entering the cell via the reduced folate carrier (RFC), Pemetrexed is converted into polyglutamate forms by the enzyme folylpolyglutamate synthetase (FPGS). These polyglutamated forms are significantly more potent inhibitors of TS and GARFT than the parent compound. By blocking these enzymes, Pemetrexed prevents the formation of DNA and RNA, leading to 'thymineless death' and the arrest of the cell cycle in the S-phase. This multi-pathway inhibition makes it harder for cancer cells to develop resistance compared to drugs that target only a single enzyme.

The pharmacodynamic effect of Pemetrexed is dose-dependent. Higher doses lead to greater inhibition of nucleotide synthesis, but also higher toxicity to rapidly dividing healthy cells (like those in the bone marrow and gut). The use of folic acid and B12 shifts the dose-response curve, allowing for effective cancer cell killing while protecting healthy tissues from the most severe 'off-target' effects. The onset of action begins shortly after infusion as the drug is polyglutamated within the cells, but the clinical effect (tumor shrinkage) is usually not visible on scans for several weeks (2-3 cycles).

| Parameter | Value |

|---|---|

| Bioavailability | 100% (Intravenous) |

| Protein Binding | ~81% (Primarily to Albumin) |

| Half-life | 3.5 hours (Normal renal function) |

| Tmax | End of 10-minute infusion |

| Metabolism | Minimal hepatic; Intracellular polyglutamation |

| Excretion | Renal (70% - 90% unchanged in urine) |

• Molecular Formula: C20H21N5O6 (as Pemetrexed acid)
• Molecular Weight: 427.41 g/mol
• Solubility: Pemetrexed disodium is soluble in water.
• Structure: It is a pyrrolo[2,3-d]pyrimidine-based antifolate. It consists of a core structure that mimics the pteridine ring of natural folates, allowing it to bind to the active sites of folate-dependent enzymes.

Pemetrexed is classified as a Folate Analog Metabolic Inhibitor. It is part of the broader category of Antimetabolites. Related medications include Methotrexate (an older antifolate) and 5-Fluorouracil (a pyrimidine analog), though Pemetrexed's multi-targeted profile distinguishes it from these agents in the treatment of lung cancer.